Skip to main content

Table 2 Parameters of iron, bone, and mineral metabolism

From: Hypophosphatemia after high-dose iron repletion with ferric carboxymaltose and ferric derisomaltose—the randomized controlled HOMe aFers study

 

A

B

 

FCM

FDI

p values of group comparison for relative changes to V2

 

V2

V3

V4

V5

p

V2

V3

V4

V5

p

p [V3]

p [V4]

p [V5]

Phosphorus [mg/dL]

3.2 ± 0.4

3.3 ± 0.5

1.9 ± 0.3

2.5 ± 0.8

< 0.001

3.6 ± 0.6

3.8 ± 0.7

2.7 ± 0.6

3.2 ± 0.6

< 0.001

0.537

0.005

0.249

FePi [%]

12 ± 6

14 ± 7

22 ± 10

15 ± 10

0.005

14 ± 9

12 ± 8

16 ± 8

11 ± 7

0.040

0.274

0.021

0.253

iFGF23 [pg/mL]

49 [42; 60]

169 [131; 201]

103 [87; 166]

57 [37; 70]

< 0.001

47 [40; 58]

40 [33; 53]

79 [47; 103]

47 [43; 51]

0.140

< 0.001

0.187

0.191

cFGF23 [RU/mL]

385 [199; 998]

192 [138; 317]

103 [79; 183]

65 [44; 122]

0.012

451 [190; 840]

79 [71; 88]

96 [55; 107]

61 [54; 76]

0.012

0.049

0.177

0.733

Calcium [mmol/L]

2.3 ± 0.1

2.3 ± 0.1

2.3 ± 0.1

2.3 ± 0.1

0.643

2.3 ± 0.1

2.3 ± 0.1

2.3 ± 0.1

2.3 ± 0.1

0.602

0.900

0.237

0.876

PTH [pg/mL]

40 [37; 55]

43 [31; 54]

42 [36; 53]

47 [41; 68]

0.231

40 [33; 52]

44 [34; 56]

35 [23; 48]

34 [26; 47]

0.114

0.194

0.128

0.018

1.25-dihydroxyvitamin D [ng/L]

55 ± 15

33 ± 9

13 ± 4

44 ± 17

< 0.001

51 ± 15

62 ± 24

25 ± 12

51 ± 14

< 0.001

< 0.001

0.002

0.159

25-Hydroxyvitamin D3 [ng/mL]

19 [10; 22]

18 [9; 25]

16 [11; 27]

12 [9; 26]

0.498

24 [21; 29]

25 [19; 32]

25 [21; 36]

23 [16; 29]

0.042

0.902

0.447

0.200

Alkaline phosphatase [U/L]

74 [52; 82]

66 [46; 79]

75 [48; 90]

69 [46; 86]

0.334

48 [41; 91]

51 [39; 85]

57 [40; 73]

48 [40; 75]

0.196

0.565

0.557

0.351

Hepcidin-25 [ng/mL]

0.9 [0.4; 1.4]

2.5 [1.6; 6.7]

26.5 [3.3; 49.6]

8.6 [3.9; 25.9]

0.045

0.6 [0.1; 1.1]

8.0 [1.6; 24.1]

17.8 [2.7; 54.6]

6.7 [2.2; 36.6]

0.025

0.342

0.929

0.924

PINP [μg/L]

51 [32; 63]

n.a.

35 [28; 47]

40 [26; 54]

0.001

57 [40; 74]

n.a.

41 [30; 49]

50 [33; 83]

0.001

n.a.

0.903

0.866

PYD [μg/g creatinine]

176 [138; 187]

n.a.

168 [126; 191]

163 [142; 193]

0.651

176 [153; 236]

n.a.

147 [133; 163]

207 [148; 258]

0.255

n.a.

0.372

0.693

DPD [μg/g creatinine]

36 [31; 42]

n.a.

36 [24; 45]

39 [25; 46]

0.563

46 [27; 58]

n.a.

31 [25; 50]

46 [30; 60]

0.386

n.a.

0.939

0.517

  1. Indicated are parameters of iron and bone metabolism at the four study visits of participants subdivided into the two treatment arms as well as relative changes between the two treatment arms between follow-up visits and the baseline visit. Presented are mean ± standard deviation or median and interquartile range, as appropriate. Longitudinal changes during the study period were first calculated within each group separately using ANOVA with repeated measures or the Friedman test, as appropriate (part A). Secondly, relative changes from baseline to each individual follow-up time point were calculated and compared between the two treatment arms by t test for two independent samples (part B). FCM ferric carboxymaltose, FDI ferric derisomaltose, FePi fractional urinary phosphorus excretion, cFGF23 c-terminal FGF23, iFGF23 intact FGF23, PTH parathyroid hormone, PINP serum n-terminal propeptide of type I collagen, PYD urinary pyridinoline, DPD urinary desoxypyridinoline. Significant values are given in bold. V2 visit 2 (day 0 = baseline), V3 visit 3 (day 1), V4 visit 4 (day 7 ± 2), V5 visit 5 (day 35 ± 2)
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us